Cargando…

Development by Genetic Immunization of Monovalent Antibodies Against Human Vasoactive Intestinal Peptide Receptor 1 (VPAC1), New Innovative, and Versatile Tools to Study VPAC1 Receptor Function

Multi-membrane spanning proteins, such as G protein-coupled receptors (GPCRs) and ion channels, are extremely difficult to purify as native proteins. Consequently, the generation of antibodies that recognize the native conformation can be challenging. By combining genetic immunization, phage display...

Descripción completa

Detalles Bibliográficos
Autores principales: Peyrassol, Xavier, Laeremans, Toon, Lahura, Vannessa, Debulpaep, Maja, El Hassan, Hassan, Steyaert, Jan, Parmentier, Marc, Langer, Ingrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895782/
https://www.ncbi.nlm.nih.gov/pubmed/29674997
http://dx.doi.org/10.3389/fendo.2018.00153
_version_ 1783313720522309632
author Peyrassol, Xavier
Laeremans, Toon
Lahura, Vannessa
Debulpaep, Maja
El Hassan, Hassan
Steyaert, Jan
Parmentier, Marc
Langer, Ingrid
author_facet Peyrassol, Xavier
Laeremans, Toon
Lahura, Vannessa
Debulpaep, Maja
El Hassan, Hassan
Steyaert, Jan
Parmentier, Marc
Langer, Ingrid
author_sort Peyrassol, Xavier
collection PubMed
description Multi-membrane spanning proteins, such as G protein-coupled receptors (GPCRs) and ion channels, are extremely difficult to purify as native proteins. Consequently, the generation of antibodies that recognize the native conformation can be challenging. By combining genetic immunization, phage display, and biopanning, we identified a panel of monovalent antibodies (nanobodies) targeting the vasoactive intestinal peptide receptor 1 (VPAC1) receptor. The nine unique nanobodies that were classified into four different families based on their CDR3 amino acid sequence and length, were highly specific for the human receptor and bind VPAC1 with moderate affinity. They all recognize a similar epitope localized in the extracellular N-terminal domain of the receptor and distinct from the orthosteric binding site. In agreement with binding studies, which showed that the nanobodies did not interfere with VIP binding, all nanobodies were devoid of any functional properties. However, we observed that the binding of two nanobodies was slightly increased in the presence of VPAC1 agonists [vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptide-27 (PACAP-27)], but decreased in the presence of VPAC1 antagonist. As no evidence of allosteric activity was seen in VIP binding studies nor in functional assays, it is, therefore, possible that the two nanobodies may behave as very weak allosteric modulators of VPAC1, detectable only in some sensitive settings, but not in others. We demonstrated that the fluorescently labeled nanobodies detect VPAC1 on the surface of human leukocytes as efficiently as a reference mouse monoclonal antibody. We also developed a protocol allowing efficient detection of VPAC1 by immunohistochemistry in paraffin-embedded human gastrointestinal tissue sections. Thus, these nanobodies constitute new original tools to further investigate the role of VPAC1 in physiological and pathological conditions.
format Online
Article
Text
id pubmed-5895782
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-58957822018-04-19 Development by Genetic Immunization of Monovalent Antibodies Against Human Vasoactive Intestinal Peptide Receptor 1 (VPAC1), New Innovative, and Versatile Tools to Study VPAC1 Receptor Function Peyrassol, Xavier Laeremans, Toon Lahura, Vannessa Debulpaep, Maja El Hassan, Hassan Steyaert, Jan Parmentier, Marc Langer, Ingrid Front Endocrinol (Lausanne) Endocrinology Multi-membrane spanning proteins, such as G protein-coupled receptors (GPCRs) and ion channels, are extremely difficult to purify as native proteins. Consequently, the generation of antibodies that recognize the native conformation can be challenging. By combining genetic immunization, phage display, and biopanning, we identified a panel of monovalent antibodies (nanobodies) targeting the vasoactive intestinal peptide receptor 1 (VPAC1) receptor. The nine unique nanobodies that were classified into four different families based on their CDR3 amino acid sequence and length, were highly specific for the human receptor and bind VPAC1 with moderate affinity. They all recognize a similar epitope localized in the extracellular N-terminal domain of the receptor and distinct from the orthosteric binding site. In agreement with binding studies, which showed that the nanobodies did not interfere with VIP binding, all nanobodies were devoid of any functional properties. However, we observed that the binding of two nanobodies was slightly increased in the presence of VPAC1 agonists [vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptide-27 (PACAP-27)], but decreased in the presence of VPAC1 antagonist. As no evidence of allosteric activity was seen in VIP binding studies nor in functional assays, it is, therefore, possible that the two nanobodies may behave as very weak allosteric modulators of VPAC1, detectable only in some sensitive settings, but not in others. We demonstrated that the fluorescently labeled nanobodies detect VPAC1 on the surface of human leukocytes as efficiently as a reference mouse monoclonal antibody. We also developed a protocol allowing efficient detection of VPAC1 by immunohistochemistry in paraffin-embedded human gastrointestinal tissue sections. Thus, these nanobodies constitute new original tools to further investigate the role of VPAC1 in physiological and pathological conditions. Frontiers Media S.A. 2018-04-05 /pmc/articles/PMC5895782/ /pubmed/29674997 http://dx.doi.org/10.3389/fendo.2018.00153 Text en Copyright © 2018 Peyrassol, Laeremans, Lahura, Debulpaep, El Hassan, Steyaert, Parmentier and Langer. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Peyrassol, Xavier
Laeremans, Toon
Lahura, Vannessa
Debulpaep, Maja
El Hassan, Hassan
Steyaert, Jan
Parmentier, Marc
Langer, Ingrid
Development by Genetic Immunization of Monovalent Antibodies Against Human Vasoactive Intestinal Peptide Receptor 1 (VPAC1), New Innovative, and Versatile Tools to Study VPAC1 Receptor Function
title Development by Genetic Immunization of Monovalent Antibodies Against Human Vasoactive Intestinal Peptide Receptor 1 (VPAC1), New Innovative, and Versatile Tools to Study VPAC1 Receptor Function
title_full Development by Genetic Immunization of Monovalent Antibodies Against Human Vasoactive Intestinal Peptide Receptor 1 (VPAC1), New Innovative, and Versatile Tools to Study VPAC1 Receptor Function
title_fullStr Development by Genetic Immunization of Monovalent Antibodies Against Human Vasoactive Intestinal Peptide Receptor 1 (VPAC1), New Innovative, and Versatile Tools to Study VPAC1 Receptor Function
title_full_unstemmed Development by Genetic Immunization of Monovalent Antibodies Against Human Vasoactive Intestinal Peptide Receptor 1 (VPAC1), New Innovative, and Versatile Tools to Study VPAC1 Receptor Function
title_short Development by Genetic Immunization of Monovalent Antibodies Against Human Vasoactive Intestinal Peptide Receptor 1 (VPAC1), New Innovative, and Versatile Tools to Study VPAC1 Receptor Function
title_sort development by genetic immunization of monovalent antibodies against human vasoactive intestinal peptide receptor 1 (vpac1), new innovative, and versatile tools to study vpac1 receptor function
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895782/
https://www.ncbi.nlm.nih.gov/pubmed/29674997
http://dx.doi.org/10.3389/fendo.2018.00153
work_keys_str_mv AT peyrassolxavier developmentbygeneticimmunizationofmonovalentantibodiesagainsthumanvasoactiveintestinalpeptidereceptor1vpac1newinnovativeandversatiletoolstostudyvpac1receptorfunction
AT laeremanstoon developmentbygeneticimmunizationofmonovalentantibodiesagainsthumanvasoactiveintestinalpeptidereceptor1vpac1newinnovativeandversatiletoolstostudyvpac1receptorfunction
AT lahuravannessa developmentbygeneticimmunizationofmonovalentantibodiesagainsthumanvasoactiveintestinalpeptidereceptor1vpac1newinnovativeandversatiletoolstostudyvpac1receptorfunction
AT debulpaepmaja developmentbygeneticimmunizationofmonovalentantibodiesagainsthumanvasoactiveintestinalpeptidereceptor1vpac1newinnovativeandversatiletoolstostudyvpac1receptorfunction
AT elhassanhassan developmentbygeneticimmunizationofmonovalentantibodiesagainsthumanvasoactiveintestinalpeptidereceptor1vpac1newinnovativeandversatiletoolstostudyvpac1receptorfunction
AT steyaertjan developmentbygeneticimmunizationofmonovalentantibodiesagainsthumanvasoactiveintestinalpeptidereceptor1vpac1newinnovativeandversatiletoolstostudyvpac1receptorfunction
AT parmentiermarc developmentbygeneticimmunizationofmonovalentantibodiesagainsthumanvasoactiveintestinalpeptidereceptor1vpac1newinnovativeandversatiletoolstostudyvpac1receptorfunction
AT langeringrid developmentbygeneticimmunizationofmonovalentantibodiesagainsthumanvasoactiveintestinalpeptidereceptor1vpac1newinnovativeandversatiletoolstostudyvpac1receptorfunction